Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding
- PMID: 2212945
- PMCID: PMC2188612
- DOI: 10.1084/jem.172.4.1143
Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding
Abstract
We studied the humoral response of mice immunized with soluble CD4-rgp120 complex, testing polyclonal and monoclonal antibodies (mAbs) with the aim of identifying molecular changes that take place after the first interaction between human immunodeficiency virus and the cell surface. The antisera had a paradoxically high syncytia-blocking titer associated with anti-CD4 specificity, while their capacity to inhibit CD4-gp120 binding was relatively modest. One of the mAbs produced from these responders blocks syncytia formation but does not inhibit CD4 interaction with gp120. Apparently, this mAb interacts with the CD4 moiety of CD4-gp120 complex and prevents a post-binding event necessary for membrane fusion and viral infection.
Similar articles
-
Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.Virology. 1995 Aug 20;211(2):583-8. doi: 10.1006/viro.1995.1441. Virology. 1995. PMID: 7544051
-
Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.J Virol. 1995 Jul;69(7):4267-73. doi: 10.1128/JVI.69.7.4267-4273.1995. J Virol. 1995. PMID: 7769687 Free PMC article.
-
Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.J Virol. 1991 Mar;65(3):1543-50. doi: 10.1128/JVI.65.3.1543-1550.1991. J Virol. 1991. PMID: 1995952 Free PMC article.
-
Molecular interactions between HIV and the T lymphocyte.Biochim Biophys Acta. 1990 Nov 14;1096(1):10-3. doi: 10.1016/0925-4439(90)90005-a. Biochim Biophys Acta. 1990. PMID: 2268680 Review. No abstract available.
-
Soluble recombinant CD4--a potential therapeutic agent for HIV infection.Biotherapy. 1990;2(2):107-18. doi: 10.1007/BF02173451. Biotherapy. 1990. PMID: 2205260 Review. No abstract available.
Cited by
-
The human fibroblast receptor for gp86 of human cytomegalovirus is a phosphorylated glycoprotein.J Virol. 1992 Aug;66(8):4834-8. doi: 10.1128/JVI.66.8.4834-4838.1992. J Virol. 1992. PMID: 1321272 Free PMC article.
-
Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.J Virol. 1996 Nov;70(11):8019-28. doi: 10.1128/JVI.70.11.8019-8028.1996. J Virol. 1996. PMID: 8892926 Free PMC article.
-
Reduced monomeric CD4 is the preferred receptor for HIV.J Biol Chem. 2010 Dec 24;285(52):40793-9. doi: 10.1074/jbc.M110.190579. Epub 2010 Oct 25. J Biol Chem. 2010. PMID: 20974843 Free PMC article.
-
Pathogenesis of human immunodeficiency virus infection.Microbiol Rev. 1993 Mar;57(1):183-289. doi: 10.1128/mr.57.1.183-289.1993. Microbiol Rev. 1993. PMID: 8464405 Free PMC article. Review.
-
A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4.J Virol. 1995 Sep;69(9):5734-42. doi: 10.1128/JVI.69.9.5734-5742.1995. J Virol. 1995. PMID: 7637018 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials